Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Fitch: Breakthrough, Fast Track Therapy Approvals Accelerating

By Pharmaceutical Processing | February 3, 2015

Closer and more frequent communications with the U.S. Food and Drug Administration (FDA) are likely the main factors leading to a shorter approval time for breakthrough drug therapies, according to Fitch Ratings. Breakthrough therapy approvals more than tripled in 2014 versus 2013.

The FDA had approved 10 breakthrough therapies through Nov. 28 of last year compared to just three approvals during the entire year prior. Five out of 10 approvals in 2014 were for drugs that treat various cancers. No breakthrough therapies were approved in 2012, as the therapy designation was enacted in July of that year.

Two breakthrough therapies in particular are attracting collaborators: Keytruda (Merck & Co.) and Opdivo (Bristol-Myers/Ono) are increasingly being studied in combination with other drugs to treat various cancers.

The number of fast track designations through September 2014 (67) were above those of 2013 (53), indicating a higher level of future FDA approvals. The fast track therapy designation is similar to that of the breakthrough therapy, although the intensity of the FDA’s involvement in expediting the approval process is somewhat less for fast track programs.

NME approvals were also up during 2014. The FDA cleared 36 novel medicines for U.S. marketing during 2014 compared to 27 in 2013. Interestingly, 11 biologics were approved in 2014 compared to only three in 2013. We continue to expect biologics to play an increasing role in drug development.

Additional information is available on www.fitchratings.com.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE